Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cidara Therapeutics

21.54
-0.8500-3.80%
Post-market: 21.540.00000.00%16:06 EDT
Volume:88.06K
Turnover:1.90M
Market Cap:235.94M
PE:-0.81
High:22.64
Open:21.88
Low:21.04
Close:22.39
Loading ...

BRIEF-Cidara Therapeutics Announces Appointment Of Frank Karbe As Chief Financial Officer

Reuters
·
19 Feb

Cidara Therapeutics Inc - Preetam Shah Departs as CFO of Cidara Therapeutics

THOMSON REUTERS
·
19 Feb

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

THOMSON REUTERS
·
19 Feb

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

GlobeNewswire
·
19 Feb

Cidara Therapeutics Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
27 Jan

Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing

Insider Monkey
·
14 Jan

Cidara Therapeutics Announces Leadership Changes and Appointments

TIPRANKS
·
08 Jan

Cidara Therapeutics Files Secondary Stock Sale Statement

MT Newswires Live
·
24 Dec 2024

Cidara Therapeutics files to sell 7.04M shares of common stock for holders

TIPRANKS
·
24 Dec 2024

Cidara Therapeutics Initiated at Outperform by RBC Capital

Dow Jones
·
13 Dec 2024

RBC Initiates Cidara Therapeutics at Outperform, Speculative Risk, With $34 Price Target

MT Newswires Live
·
13 Dec 2024

Venrock Healthcare Capital Partners Iii Lp Reports 9.99% Passive Stake in Cidara Therapeutics Inc as of November 26 - SEC Filing

THOMSON REUTERS
·
05 Dec 2024

Cidara Therapeutics completes enrollment of Phase 2b NAVIGATE trial

TIPRANKS
·
04 Dec 2024

Cidara Therapeutics Completes Enrollment of Phase 2B Navigate Trial Evaluating Cd388 for Prevention of Seasonal Influenza

THOMSON REUTERS
·
04 Dec 2024

Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

GlobeNewswire
·
04 Dec 2024

Tcg Crossover Gp Ii, Llc Reports 9.2% Passive Stake in Cidara Therapeutics Inc as of Nov 26 - SEC Filing

THOMSON REUTERS
·
04 Dec 2024